首页> 外文期刊>European journal of human genetics: EJHG >GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells
【24h】

GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells

机译:GluD1是从MECP2突变和CDKL5突变的iPS细胞神经元分化中常见的改变参与者

获取原文
获取原文并翻译 | 示例
       

摘要

Rett syndrome is a monogenic disease due to de novo mutations in either MECP2 or CDKL5 genes. In spite of their involvement in the same disease, a functional interaction between the two genes has not been proven. MeCP2 is a transcriptional regulator; CDKL5 encodes for a kinase protein that might be involved in the regulation of gene expression. Therefore, we hypothesized that mutations affecting the two genes may lead to similar phenotypes by dysregulating the expression of common genes. To test this hypothesis we used induced pluripotent stem (iPS) cells derived from fibroblasts of one Rett patient with a MECP2 mutation (p.Arg306Cys) and two patients with mutations in CDKL5 (p.Gln347Ter and p.Thr288Ile). Expression profiling was performed in CDKL5-mutated cells and genes of interest were confirmed by real-time RT-PCR in both CDKL5-and MECP2-mutated cells. The only major change in gene expression common to MECP2- and CDKL5-mutated cells was for GRID1, encoding for glutamate D1 receptor (GluD1), a member of the delta-family of ionotropic glutamate receptors. GluD1 does not form AMPA or NMDA glutamate receptors. It acts like an adhesion molecule by linking the postsynaptic and presynaptic compartments, preferentially inducing the inhibitory presynaptic differentiation of cortical neurons. Our results demonstrate that GRID1 expression is downregulated in both MECP2- and CDKL5-mutated iPS cells and upregulated in neuronal precursors and mature neurons. These data provide novel insights into disease pathophysiology and identify possible new targets for therapeutic treatment of Rett syndrome.
机译:Rett综合征是一种单基因疾病,归因于MECP2或CDKL5基因的从头突变。尽管它们参与相同的疾病,但两个基因之间的功能相互作用尚未得到证实。 MeCP2是转录调节子; CDKL5编码可能参与基因表达调控的激酶蛋白。因此,我们假设影响两个基因的突变可能通过失调常见基因的表达而导致相似的表型。为了验证这一假设,我们使用了诱导多能干细胞(iPS),该细胞来自一名具有MECP2突变的Rett患者(p.Arg306Cys)和两名患有CDKL5突变的患者(p.Gln347Ter和p.Thr288Ile)的成纤维细胞。在CDKL5突变的细胞中进行表达谱分析,并通过实时RT-PCR在CDKL5和MECP2突变的细胞中确认目标基因。 MECP2和CDKL5突变的细胞共有的基因表达的唯一主要变化是GRID1,它编码离子型谷氨酸受体δ-家族的成员谷氨酸D1受体(GluD1)。 GluD1不形成AMPA或NMDA谷氨酸受体。它通过连接突触后和突触前区室,像粘附分子一样起作用,优先诱导皮层神经元的抑制性突触前分化。我们的结果证明,在MECP2和CDKL5突变的iPS细胞中GRID1表达下调,在神经元前体和成熟神经元中上调。这些数据提供了对疾病病理生理学的新颖见解,并确定了治疗Rett综合征的新靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号